Illinois Municipal Retirement Fund Lowers Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Illinois Municipal Retirement Fund lowered its holdings in Certara, Inc. (NASDAQ:CERT) by 7.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,453 shares of the company’s stock after selling 4,805 shares during the period. Illinois Municipal Retirement Fund’s holdings in Certara were worth $612,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brown Brothers Harriman & Co. purchased a new stake in shares of Certara in the third quarter valued at $27,292,000. Kopion Asset Management LLC grew its position in Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after acquiring an additional 175,005 shares during the period. Massachusetts Financial Services Co. MA grew its position in Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after acquiring an additional 1,128,006 shares during the period. Vontobel Holding Ltd. purchased a new stake in Certara during the fourth quarter valued at about $1,295,000. Finally, Barclays PLC grew its position in Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after acquiring an additional 46,880 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CERT shares. Robert W. Baird lowered their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays boosted their price objective on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Certara presently has a consensus rating of “Moderate Buy” and an average price target of $15.83.

Certara Trading Down 0.3 %

NASDAQ:CERT opened at $11.94 on Tuesday. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -59.70, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The business’s 50-day simple moving average is $12.48 and its 200 day simple moving average is $11.63. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.